RATIONALE: Immediate graft performance after lung transplantation is associated with short- and long-term clinical outcomes. However, the biologic mechanism that determines outcomes is not fully understood. OBJECTIVES: To investigate the impact of cell death signals at 24 and 48 hours after lung transplantation on short- and long-term clinical outcomes. METHODS: Plasma samples were collected pretransplantation and at 24 and 48 hours after transplant from 60 bilateral lung transplant recipients. Ten patients had primary graft dysfunction (PGD) grade 3 (PaO2/FiO2 ratio <200 or on extracorporeal membrane oxygenation support) at 72 hours after transplant (PGD group). The remaining 50 patients were defined as the control group. Levels of plasma M30 (signifying epithelial apoptosis), M65 (signifying epithelial apoptosis plus necrosis), and high-mobility group box 1 protein (HMGB-1; signifying necrosis of all cell types) were measured by ELISA and correlated with clinical outcomes. Survival analyses were performed using Kaplan-Meier curves and Cox proportional hazards regression. Prediction accuracy of markers was assessed by calculated area under the curve of receiver operating characteristic graph. MEASUREMENTS AND MAIN RESULTS: The PGD group had significantly higher M30 and M65 levels at 24 and 48 hours after transplant compared with the control group. There was no significant difference in HMGB-1. Area under the curve for 1-year survival was 0.86, 0.93, and 0.51 for M30, M65, and HMGB-1 at 48 hours, respectively. Survival analysis showed that higher M30 and M65 levels at 24 and 48 hours were significantly associated with worse survival. M65 at 48 hours remained significant even after adjustment for PGD. HMGB-1 was not significantly associated with survival. CONCLUSIONS: Recipient plasma concentration of epithelial cell death markers (M30, M65) after lung transplantation is negatively correlated with early graft performance and long-term survival.
RATIONALE: Immediate graft performance after lung transplantation is associated with short- and long-term clinical outcomes. However, the biologic mechanism that determines outcomes is not fully understood. OBJECTIVES: To investigate the impact of cell death signals at 24 and 48 hours after lung transplantation on short- and long-term clinical outcomes. METHODS: Plasma samples were collected pretransplantation and at 24 and 48 hours after transplant from 60 bilateral lung transplant recipients. Ten patients had primary graft dysfunction (PGD) grade 3 (PaO2/FiO2 ratio <200 or on extracorporeal membrane oxygenation support) at 72 hours after transplant (PGD group). The remaining 50 patients were defined as the control group. Levels of plasma M30 (signifying epithelial apoptosis), M65 (signifying epithelial apoptosis plus necrosis), and high-mobility group box 1 protein (HMGB-1; signifying necrosis of all cell types) were measured by ELISA and correlated with clinical outcomes. Survival analyses were performed using Kaplan-Meier curves and Cox proportional hazards regression. Prediction accuracy of markers was assessed by calculated area under the curve of receiver operating characteristic graph. MEASUREMENTS AND MAIN RESULTS: The PGD group had significantly higher M30 and M65 levels at 24 and 48 hours after transplant compared with the control group. There was no significant difference in HMGB-1. Area under the curve for 1-year survival was 0.86, 0.93, and 0.51 for M30, M65, and HMGB-1 at 48 hours, respectively. Survival analysis showed that higher M30 and M65 levels at 24 and 48 hours were significantly associated with worse survival. M65 at 48 hours remained significant even after adjustment for PGD. HMGB-1 was not significantly associated with survival. CONCLUSIONS: Recipient plasma concentration of epithelial cell death markers (M30, M65) after lung transplantation is negatively correlated with early graft performance and long-term survival.
Authors: Ciara M Shaver; Nancy Wickersham; J Brennan McNeil; Hiromasa Nagata; Adam Miller; Stuart R Landstreet; Jamie L Kuck; Joshua M Diamond; David J Lederer; Steven M Kawut; Scott M Palmer; Keith M Wille; Ann Weinacker; Vibha N Lama; Maria M Crespo; Jonathan B Orens; Pali D Shah; Chadi A Hage; Edward Cantu; Mary K Porteous; Gundeep Dhillon; John McDyer; Julie A Bastarache; Jason D Christie; Lorraine B Ware Journal: JCI Insight Date: 2018-01-25
Authors: Davide Scozzi; Mohsen Ibrahim; Fuyi Liao; Xue Lin; Hsi-Min Hsiao; Ramsey Hachem; Laneshia K Tague; Alberto Ricci; Hrishikesh S Kulkarni; Howard J Huang; Seiichiro Sugimoto; Alexander S Krupnick; Daniel Kreisel; Andrew E Gelman Journal: Am J Transplant Date: 2019-01-25 Impact factor: 8.086
Authors: Kevin Budding; Eduard A van de Graaf; Tineke Kardol-Hoefnagel; Erik-Jan D Oudijk; Johanna M Kwakkel-van Erp; C Erik Hack; Henny G Otten Journal: Front Immunol Date: 2017-03-21 Impact factor: 7.561
Authors: Hrishikesh S Kulkarni; Kristy Ramphal; Lina Ma; Melanie Brown; Michelle Oyster; Kaitlyn N Speckhart; Tsuyoshi Takahashi; Derek E Byers; Mary K Porteous; Laurel Kalman; Ramsey R Hachem; Melanie Rushefski; Ja'Nia McPhatter; Marlene Cano; Daniel Kreisel; Masina Scavuzzo; Brigitte Mittler; Edward Cantu; Katrine Pilely; Peter Garred; Jason D Christie; John P Atkinson; Andrew E Gelman; Joshua M Diamond Journal: JCI Insight Date: 2020-09-03